Consensus or Controversy, Issue 5: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Use of Sipuleucel-T in the Management of Metastatic Castration-Resistant Prostate Cancer

To see the complete question and investigator responses, move your mouse over the related topic.
Click the "Select Faculty Commentary" button to review full commentary (login required).

PC = prostate cancer; PSADT = PSA doubling time; Chemo = chemotherapy; Enza = enzalutamide;
Abi = abiraterone; Sip-T = sipuleucel-T